Dr. Lal PathLabs Ltd

Dr Lal Pathlabs  (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq' X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq' X system features Illumina's cutting-edge XLEAP-SBS' chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. 'With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,' said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. 'This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.' Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing ('NGS'), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity. Powered by Capital Market - Live

Dr Lal Pathlabs  (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq' X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq' X system features Illumina's cutting-edge XLEAP-SBS' chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. 'With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,' said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. 'This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.' Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing ('NGS'), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity. Powered by Capital Market - Live

Dr. Lal PathLabs announced that the Annual General Meeting(AGM) of the company will be held on 28 June 2025.Powered by Capital Market - Live

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 25 April 2025, inter alia, have recommended the final dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Dr Lal Pathlabs rose 83.20% to Rs 154.80 crore in the quarter ended March 2025 as against Rs 84.50 crore during the previous quarter ended March 2024. Sales rose 10.49% to Rs 602.60 crore in the quarter ended March 2025 as against Rs 545.40 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.18% to Rs 487.10 crore in the year ended March 2025 as against Rs 357.70 crore during the previous year ended March 2024. Sales rose 10.55% to Rs 2461.40 crore in the year ended March 2025 as against Rs 2226.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales602.60545.40 10 2461.402226.60 11 OPM %28.0526.53 -28.2627.36 - PBDT189.80156.50 21 766.60649.10 18 PBT153.40119.90 28 624.70505.50 24 NP154.8084.50 83 487.10357.70 36 Powered by Capital Market - Live

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 25 April 2025.Powered by Capital Market - Live

Dr Lal Pathlabs has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry - a breakthrough test for accurately identifying different types of Amyloid proteins. With this launch, Dr Lal Pathlabs becomes the first diagnostic chain in South Asia to offer this highly specialized test. Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected. Commenting on the launch, Shankha Banerjee, CEO of Dr. Lal PathLabs, said, 'Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution.' Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).Powered by Capital Market - Live

Aditya Birla Real Estate Ltd, Can Fin Homes Ltd, Paisalo Digital Ltd and Religare Enterprises Ltd are among the other losers in the BSE's 'A' group today, 25 February 2025.Dr Lal Pathlabs Ltd tumbled 6.07% to Rs 2432 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 6240 shares were traded on the counter so far as against the average daily volumes of 1867 shares in the past one month.Aditya Birla Real Estate Ltd lost 4.91% to Rs 1889.95. The stock was the second biggest loser in 'A' group.On the BSE, 5558 shares were traded on the counter so far as against the average daily volumes of 7220 shares in the past one month.Can Fin Homes Ltd crashed 4.67% to Rs 577.25. The stock was the third biggest loser in 'A' group.On the BSE, 47911 shares were traded on the counter so far as against the average daily volumes of 15995 shares in the past one month.Paisalo Digital Ltd corrected 4.66% to Rs 38.28. The stock was the fourth biggest loser in 'A' group.On the BSE, 1.17 lakh shares were traded on the counter so far as against the average daily volumes of 1.49 lakh shares in the past one month.Religare Enterprises Ltd fell 4.54% to Rs 238.5. The stock was the fifth biggest loser in 'A' group.On the BSE, 64267 shares were traded on the counter so far as against the average daily volumes of 1.31 lakh shares in the past one month.Powered by Capital Market - Live

Dr Lal Pathlabs has allotted 4,000 equity shares under ESOP on 18 February 2025. With this allotment, the paid up equity share capital has increased to Rs 83,59,17,350/- divided into 8,35,91,735 equity shares of Rs 10/-each. Powered by Capital Market - Live

Net profit of Dr Lal Pathlabs rose 18.94% to Rs 96.70 crore in the quarter ended December 2024 as against Rs 81.30 crore during the previous quarter ended December 2023. Sales rose 10.73% to Rs 596.70 crore in the quarter ended December 2024 as against Rs 538.90 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales596.70538.90 11 OPM %25.8126.09 - PBDT173.80151.90 14 PBT138.30115.90 19 NP96.7081.30 19 Powered by Capital Market - Live